STAAR Surgical Company logo

STAAR Surgical Company

STAA

NASDAQHealthcareMedical - Instruments & Supplies

Previous close

$23.14

+$0.07 · +0.30%

Aug 21, 4:00 PM ET

STAA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

49

Fair Value

Momentum

46

Neutral

Sentiment

68

Bullish

Risk resilience

49

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Warren Foust
Listed since
Feb 24, 1992
Employees
921

Market position

Day range

Current $23.14

52-week range

Current $23.14

Open
$23.15
Previous close
$23.07
Volume
698.5K
0.77× average
Average volume
905.67K
Average daily volume
Market cap
1.15B USD
Beta
1.23
Market reference 1
50-day average
$26.2818
-11.95% below average
200-day average
$24.2038
-4.39% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.06B USD
P/E (TTM)
289.25×
P/B (TTM)
3.19×
P/S (TTM)
3.39×
EV / EBITDA
-14.35×
Earnings yield
-6.88%
Free cash flow yield
-3.42%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
76.23%
Operating margin
10.32%
Net margin
1.13%
Return on equity
-23.37%
Return on assets
-17.43%
Return on invested capital
-11.26%

Financial health

Debt / equity
0.1×
Current ratio
4.55×
Altman Z-score
7.45
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends90%45%0%-45%Gross margin, FY2021: 77.51%Gross margin, FY2022: 78.55%Gross margin, FY2023: 78.36%Gross margin, FY2024: 76.32%Gross margin, FY2025: 76.19%Operating margin, FY2021: 14.47%Operating margin, FY2022: 15.40%Operating margin, FY2023: 8.71%Operating margin, FY2024: -4.02%Operating margin, FY2025: -19.19%Net margin, FY2021: 11.94%Net margin, FY2022: 13.95%Net margin, FY2023: 6.62%Net margin, FY2024: -6.44%Net margin, FY2025: -33.60%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 77.51%. Gross margin FY2022 78.55%. Gross margin FY2023 78.36%. Gross margin FY2024 76.32%. Gross margin FY2025 76.19%. Operating margin FY2021 14.47%. Operating margin FY2022 15.40%. Operating margin FY2023 8.71%. Operating margin FY2024 -4.02%. Operating margin FY2025 -19.19%. Net margin FY2021 11.94%. Net margin FY2022 13.95%. Net margin FY2023 6.62%. Net margin FY2024 -6.44%. Net margin FY2025 -33.60%.

Income trends

Revenue

239.44M USD-23.72%

Operating income

−45.95M USD-264.33%

Net income

−80.45M USD-298.10%
Income trends across reported periods362.7M USD201.56M USD40.41M USD−120.73M USDRevenue, FY2021: 230.47M USDRevenue, FY2022: 284.39M USDRevenue, FY2023: 322.42M USDRevenue, FY2024: 313.9M USDRevenue, FY2025: 239.44M USDOperating income, FY2021: 33.34M USDOperating income, FY2022: 43.8M USDOperating income, FY2023: 28.1M USDOperating income, FY2024: −12.61M USDOperating income, FY2025: −45.95M USDNet income, FY2021: 27.51M USDNet income, FY2022: 39.67M USDNet income, FY2023: 21.35M USDNet income, FY2024: −20.21M USDNet income, FY2025: −80.45M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 230.47M USD. Revenue FY2022 284.39M USD. Revenue FY2023 322.42M USD. Revenue FY2024 313.9M USD. Revenue FY2025 239.44M USD. Operating income FY2021 33.34M USD. Operating income FY2022 43.8M USD. Operating income FY2023 28.1M USD. Operating income FY2024 −12.61M USD. Operating income FY2025 −45.95M USD. Net income FY2021 27.51M USD. Net income FY2022 39.67M USD. Net income FY2023 21.35M USD. Net income FY2024 −20.21M USD. Net income FY2025 −80.45M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue239.44M USD313.9M USD322.42M USD284.39M USD230.47M USD
Cost of goods sold57.02M USD74.32M USD69.76M USD61.01M USD51.84M USD
Gross profit182.42M USD239.58M USD252.65M USD223.38M USD178.64M USD
Research and development40.06M USD53.97M USD44.4M USD35.98M USD33.86M USD
Selling, general, and administrative188.31M USD198.22M USD180.15M USD143.6M USD111.44M USD
Operating expenses228.37M USD252.19M USD224.55M USD179.58M USD145.3M USD
Interest income4.59M USD5.91M USD6.99M USD2.45M USD
Interest expense38K USD
Depreciation and amortization8.73M USD6.89M USD5.12M USD4.51M USD3.64M USD
Operating income−45.95M USD−12.61M USD28.1M USD43.8M USD33.34M USD
Net income−80.45M USD−20.21M USD21.35M USD39.67M USD27.51M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
-172.75%
11 comparable reports
Latest EPS result
0.16
Estimate 0.22 · Miss by 27.73%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.540.14-0.27-0.67Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 11, 2025: actual -0.5, estimate 0.02, surprise -2600.00%, Miss. Q2 2025, reported May 7, 2025: actual -0.52, estimate -0.59, surprise +11.86%, Beat. Q3 2025, reported Aug 6, 2025: actual -0.34, estimate -0.56, surprise +39.38%, Beat. Q4 2025, reported Nov 5, 2025: actual 0.46, estimate 0.18, surprise +155.56%, Beat. Q1 2026, reported Mar 3, 2026: actual -0.2, estimate 0.18, surprise -211.11%, Miss. Q2 2026, reported May 13, 2026: actual 0.38, estimate 0.054, surprise +600.85%, Beat. Q3 2026, reported Aug 12, 2026: actual 0.16, estimate 0.221, surprise -27.73%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.12, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates99.09M78.04M56.99M35.94MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 11, 2025: actual 48.95M USD, estimate 77.47M USD, surprise -36.82%, Miss. Q2 2025, reported May 7, 2025: actual 42.59M USD, estimate 40.3M USD, surprise +5.68%, Beat. Q3 2025, reported Aug 6, 2025: actual 44.32M USD, estimate 40.5M USD, surprise +9.43%, Beat. Q4 2025, reported Nov 5, 2025: actual 94.73M USD, estimate 75.54M USD, surprise +25.40%, Beat. Q1 2026, reported Mar 3, 2026: actual 57.8M USD, estimate 74.96M USD, surprise -22.89%, Miss. Q2 2026, reported May 13, 2026: actual 93.52M USD, estimate 78.72M USD, surprise +18.81%, Beat. Q3 2026, reported Aug 12, 2026: actual 93.54M USD, estimate 90.6M USD, surprise +3.24%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 79.1M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$31.50

36.13% upside
Past 12 months12-month forecastHigh $40.00Average $31.50Low $27.00

Rating distribution

16 ratings
Strong buy00%
Buy425%
Hold1063%
Sell213%
Strong sell00%

Recent analyst actions

12 institutions
UBSmaintainSell
JefferiesmaintainBuy

STAA news

Corporate actions

Corporate action history

Stock split

Effective May 18, 1992

1:2

Stock split

Effective Nov 1, 1990

1:2

Stock split

Effective Nov 9, 1984

2:1

Stock split

Effective Jul 3, 1984

2:1

STAA peers

ETFs holding STAA

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research STAA

research.disclaimer